QamarJKhanMD

Oncology • Fairway, KS

Associate Professor, Internal Medicine, University Kansas School of Medicine

Join to view full profile

Dr. Khan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Khan's full profile

Already have an account?

Office
2330 Shawnee Mission Pkwy
Ste 210
Fairway, KS 66205
Phone+1 913-588-6000

Education & Training

University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2004
Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 1993 - 1997
King Edward Medical UniversityClass of 1986

Certifications & Licensure

MO State Medical License 2021 - 2026
KS State Medical License 2000 - 2025
SC State Medical License 1997 - 2013
CT State Medical License 1995 - 2000
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias Start of enrollment: 2009 Mar 01
Completed
Phase 2
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Start of enrollment: 2009 May 01
Completed
Phase 2
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression Start of enrollment: 2009 Jul 01
Completed
Phase 2
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Start of enrollment: 2011 Feb 01
Unknown status
Phase 2
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 1
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Start of enrollment: 2014 Feb 28
Completed
Phase 1
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Capecitabine in Metastatic Breast and GI Cancers Start of enrollment: 2015 Oct 05
Active, not recruiting
Phase 2
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer Start of enrollment: 2016 Feb 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers.
Jason I Griffiths, Patrick A Cosgrove, Eric F Medina, Aritro Nath, Jinfeng Chen
Nature Communications. 2025-03-03
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancer.
Veronica Jones, Hongwei Holly Yin, Yate-Ching Yuan, Yongzhe Wang, Sierra Min Li
Scientific Reports. 2025-02-28
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial.
Qamar J Khan, Colleen Bohnenkamp, Taylor E Monson, Milind A Phadnis, Lauren Clark
JCO Oncology Advances. 2025-01-01

Journal Articles

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Amanda Amin, Jamie Wagner, Qamar J Khan, Roy A Jensen, Joshua M Mammen, Priyanka Sharma, Jennifer R Klemp, Clinical Cancer Research